INTELLIGENT TRANSDERMAL DRUG DELIVERY SYSTEM AND METHOD WITH INTEGRATED DISPLAY, CONTROLLED DOSAGE, AND DIGITAL SAFETY SYNCHRONIZATION.

Abstract

The invention addresses technical problems arising from leaving dose control to the user's initiative. In order to solve this; at least one electronic device that communicates wirelessly with at least one interface. a device (10), the lock status of the device (10), the next dose time, the battery level and mobile application synchronization information displayed to the user in real time at least an integrated screen (1) to prevent unintended or unauthorized use of the user's peer At least one multi-trigger system (2) that enables the device (10) to be activated by pressing the timer, Before the determined dose range is completed, at least one physical impedance prevents the operation of the device (10). mechanical locking mechanism (3), where drug-containing transdermal patches are placed, At least one patch reservoir of replaceable structure (4), controlled drug-containing transdermal patch at least one belt feeding mechanism that enables it to be physically advanced in this way (5), At least one mechanical cutting / separation that enables the conveyor belt to be cut to a specified length. unit (6) ensures that the band is applied to the skin surface with at least one constant and sufficient pressure. The printing element performs the belt advancement and application movements, and the belt in question... at least one drive which is a motor or manual drive that gives movement to the feeding mechanism (5) The system is at least a gear / belt / shaft system that transmits motor movement to the feed mechanism. a power transmission mechanism that manages all functions of the device (10) and the mobile enabling communication with the application and the device (10) outside the defined dose ranges to prevent it from working at times the mechanical locking mechanism (3) programmed to remain in the closed / active state and after each application a mechanism that stores the application time in memory and keeps it there until the next dose time. At least one control unit that keeps the locking mechanism (3) active, the device (10) containing at least one energy storage unit that provides the energy necessary for its operation a transdermal drug delivery device (10) that includes and synchronizes with a mobile application It is related to the system (100) and method.

Description

1 TARIFF INTEGRATED DISPLAY, CONTROLLED DOSAGE AND DIGITAL SECURITY. SMART TRANSDERMAL DRUG DELIVERY WITH SYNCHRONIZATION SYSTEM and METHOD Technical Area This invention allows for the controlled and safe delivery of drug-containing transdermal patches to the skin. a device that enables its implementation and a digital system and method that works integrated with this device It is related to. State of the Art Transdermal drug patches allow for the controlled release of specific drugs through the skin. Although widely used for this purpose, current application methods vary by technique. and includes user-related issues. In the known state of the technique, drug administration through the skin / transdermal drug delivery 15 Within this scope, drug applications primarily involve the use of pre-fabricated single-bandage products by the user. This is performed by manually applying it directly to the skin. In this method, the user removes the tape from its packaging and applies it to the desired area. and manages the usage time through its own monitoring. This situation is flawed during implementation. This can lead to problems such as placement, insufficient contact, or irregular pressure. These 20 types... Errors can directly affect the effectiveness of the medication, leading to undesirable outcomes in the treatment process. This is possible. In other words, one of the main disadvantages of this approach is... The application is entirely dependent on user skill. The tapes must be applied correctly to the skin. such as failure to install, insufficient pressure being applied, or incorrect positioning. These conditions can negatively affect the absorption performance of the drug. Also, 25 in each application. Failure to maintain a standard pressure and placement quality leads to variability in treatment effectiveness. This is the reason. However, in current solutions, dose control largely depends on user monitoring. They are being left behind, and failure to adhere to the specified time intervals, forgetting, or consecutively Situations like these pose a risk of overdose. Especially chronic diseases 30 And this risk becomes even more critical in situations requiring regular medication. Current Solutions include mobile applications or timers to remind users to take their medication. 2 Although systems exist, such digital solutions are only passive, informing the user. These are systems that cannot interfere with the physical implementation process. In other words, While digital reminder applications exist, these systems lack physical implementation. It is unable to intervene in the process and remains only at the level of passive warning. Therefore... Situations such as user error, forgetfulness, or deliberate / incorrect reuse 5 It cannot be prevented and the risk of overdose remains. On the other hand, some medical Although advanced systems exist that provide dose control in applications, these systems are generally relying on invasive methods (e.g., injection pumps) or high-cost and It involves complex structures. This makes it impractical and accessible for everyday use. This makes it difficult to offer a solution. 10 In addition, the processes of storing, transporting and applying drug patches in existing systems A device structure that is independent of each other but manages these processes in an integrated way. There are no issues. The tapes are transported in individual packages for hygiene and ease of use. This creates limitations in that respect. In addition, current transdermal patch systems provide the user with information about device status, usage time, 15 By providing critical information such as dosage information and system lockout in real time, it guides the user. a mechanical and integrated system that monitors usage conditions and prevents misuse. There is no interface structure or digital control infrastructure. This situation is particularly problematic in regular settings. negatively impacts user experience and safety in situations where drug use is necessary. It affects. 20 Another technical challenge is ensuring that patches for different types of medication are safe, hygienic, and standardized. an integrated mechanical system for storing and implementing in some way The problem is that it is not available. Existing solutions involve external factors in the processes of transporting and applying the tapes. It is susceptible to influences and has limitations in terms of user experience and security. 25 These disadvantages reveal the user-dependent, uncontrolled, and fragmented nature of existing solutions. It is putting in place a more secure system that integrates mechanical, digital, and user interface components. This demonstrates the need for a systematic solution. A patent numbered WO2023049907 (A1) in the prior art The document describes an AI-based image of pimples, acne, or lesions on the skin. Automatically detects, tracks, and completes using a processing / camera system (machine vision). 3 micro-needles or cartridge syringes are used to inject these substances into the targets. a handheld electromechanical skin device that administers precise liquid medication or supplement injections. It is a treatment device. Although the device in question contains a processing unit / control unit, containing a battery / energy storage unit and connected to an external mobile application / computer system. Although it is an electromechanical device capable of wireless communication (Bluetooth, Wi-Fi, etc.), the medicine is in liquid form. storing the liquid (liquid, vaccine, or supplement) in a syringe or cartridge and micro- It is injected under the skin using needles. The document describes a solid / gel transdermal patch. The document does not mention a drug in solid / gel form. Furthermore, the device mentioned in the document refers to a solid / gel drug. a band that mechanically advances a band in transdermal form and cuts it to a specified length It does not have a feeding and mechanical cutting / separation unit architecture. 10 that opens in the form of a lid. and the device does not have an integrated screen and the drug conveyor belts in question are loaded There is no reservoir. Brief Description of the Invention The aim of this invention is to deliver drug-containing transdermal patches to the skin in a controlled and safe manner. the production of a device that enables its implementation and a digital system that works integrated with this device and 15 The goal is to implement the working method. Within the scope of this purpose, drug administration through the skin / transdermal drug delivery The drug patches used within this scope are controlled, safe, and independent of the user. It ensures standardized application to the skin; dose monitoring is systematized. By doing so, the risks of misuse, incomplete application, and overdose are eliminated. 20 On the other hand, in line with this purpose, the invention arises depending on the user in existing systems. In order to resolve application errors that may occur, the medication patches are stored in roll form and a front and back of the skin surface via a mechanical feeding, cutting and application mechanism. It offers a device structure in which the pressure elements are placed in a controlled manner. Thus By ensuring a standard pressure and positioning in each application, continuity in drug absorption is ensured and 25 Accuracy is ensured. The invention also benefits from the technical aspects arising from leaving dose control to the user's initiative. A digital control system that works in sync with a mobile application to solve problems. This includes preventing the device from operating outside of predefined dose ranges. It is equipped with a locking mechanism. In this context, the system only alerts the user with 30... Unlike passive solutions, it directly controls the mechanical operating functions of the device. 4 It offers an active control structure that limits it. However, on the device The integrated display shows the time for the next dose, the device's lock status, and battery level. Level and mobile application synchronization information is provided to the user in real time. This is being transferred; thus, the usage process becomes transparent, traceable, and manageable. is being brought. 5 Additionally, the invention activates the device to prevent unintentional or unauthorized use. To be activated, there are two buttons located on the front surface and at least one button located on the rear surface. It includes a multi-trigger mechanism that requires the simultaneous pressing of the button. This structure allows for accidental triggers that can be carried out, especially by children. by blocking it, it creates a physical security layer and with the digital locking system 10 Together, they offer an integrated security approach. In conclusion, the invention includes a mechanical application system, digital dose control, and real-time functionality. By integrating the user interface and multiple physical security mechanisms, the existing against user dependency, lack of control and security vulnerabilities found in solutions It is developing a comprehensive and technical solution. 15 Therefore, this invention, compared to existing solutions in the field of transdermal drug delivery, offers the following advantages: It includes technical advantages and unique features: • Integrated mechanical + digital dose control: The system not only warns the user but also directly restricts the device's operation. It eliminates the risk of overdose by offering an active control mechanism. 20 • Roller-based automatic application mechanism: The storage, automatic feeding, and cutting of medication patches in a cassette-type system. Its implementation ensures a hygienic, standardized, and user-independent application. • Standardized quality of application: Thanks to the front and rear printing elements, it provides even pressure and accurate 25° with every use. By ensuring proper placement, continuity of drug absorption is achieved. • Two-way control via mobile application: Dose scheduling, usage tracking, and device activation are managed digitally. A systematic treatment process is established. • Real-time user interface with integrated display: Provides the user with dose time, lock status, battery level, and synchronization with the application. By providing information in real-time, security and transparency in usage are increased. • Multiple-button physical safety mechanism (child-safe): To activate the device, press the multiple buttons located on the front and back surfaces. The need for simultaneous printing, involuntary triggers, and especially child-induced triggers. obstacles. • Security through physical locking: Thanks to both digital control and a mechanical locking system, the device controls the specified dose. It cannot be operated before the interval is complete. 10 • Modular structure compatible with different drug bandages: Patches for different types of treatment can be safely applied using the same device. It enables its use. This invention encompasses devices, systems, and methods considered together. The invention involves the use of existing passive components. Unlike reminder systems, the device's operation outside of the specified dose ranges is 15 They are necessarily blocked both mechanically and digitally. Additionally, the device can be operated by pressing the buttons located on the front and back surfaces simultaneously. The multiple trigger mechanism requiring a press is an important feature that prevents unintentional use. It has emerged as a physical security element. Explanation of Figures 20 Figure 1. Representative top view of the device subject to the invention with the screen closed. Figure 2. Top perspective representation of the device subject to the invention with the screen on. Figure 3. General block diagram of the system described in the invention. Explanation of References in Figures To better understand the invention, the numbers in the figures correspond to the following: 25 100. System 10. Device 1. Screen 2. Multiple Trigger System 30 6 3. Locking Mechanism 4. Roll Tape Reservoir 5. Belt Feeding Mechanism 6. Cutting / Separating Unit Detailed Description of the Invention The system in question (100) leaves dose control to the user's initiative. To resolve the resulting technical issues, it works in sync with a mobile application. a digital control system, with at least one electronic device containing an interface and wireless 10 It includes at least one communicating device (10). Controlled and safe application of drug-containing transdermal patches to the skin. The device in question (10) provides the next dose time; the device in question (10) locks status, next dose time, battery level, and synchronization with the relevant mobile application. at least one integrated display (1) showing information such as this to the user in real time, request 15 To prevent unauthorized or off-site use, the user must press the device simultaneously (10) at least one multiple trigger system (2) that enables it to activate, specified dose range at least one mechanical lock that physically prevents the operation of the device (10) before it is full mechanism (3), the most replaceable structure in which drug-containing transdermal patches are placed. a small patch reservoir (4), transdermal 20 containing drug with motor or manual drive assist system at least one belt feed that enables the belt to be physically advanced in a controlled manner mechanism (5) enables at least one of the following to cut the advanced belt to a specified length. mechanical cutting / separation unit (6), with fixed and sufficient pressure on the skin surface of the tape at least one printing element (in the figures) which is the mechanical surface that enables its application (not numbered), the 25 in question perform the belt advancement and application movements. At least one motor or manual drive that drives the belt feeding mechanism (5) a drive system is a gear / belt / shaft system that transmits motor motion to the feed mechanism at least one power transmission mechanism that manages all functions of the device (10) enabling communication with the mobile application and the device (10) outside of the defined dose ranges to prevent it from working at times the mechanical locking mechanism (3) 30 programmed to remain in the off / on position after each application a mechanism that stores the application time in memory and keeps it there until the next dose time. At least one control unit that keeps the locking mechanism (3) active, the device (10) 7 At least one portable energy storage unit that provides the necessary energy, preferably a battery. It includes. The belt feeding mechanism (5) can be of the following types: roller, gear, drive, etc. The drive system is an electric motor or manual motor that moves the belt feed mechanism (5). The moving element; the power transmission mechanism is the drive system and the belt feed 5 gears, shafts, belts or similar transmissions that provide motion transmission between the mechanisms (5) are elements. Multiple trigger system (2), two on the front surface and at least one on the rear surface of the device (10). They are positioned as follows, and the input elements are in the form of push buttons. It consists of 10. Mechanical locking mechanism (3), drive system or belt feed mechanism (5) a pin mechanism, locking gear, or latch that physically prevents its movement or it can be an electromechanical actuator-controlled locking element. The patch reservoir (4) is suitable for placing drug-containing transdermal patches in roll form. It is in a closed and replaceable module structure. On the other hand, the integrated screen (1) extends upwards 15 It has a hinged cover. When the screen is lifted up, the roller underneath rolls up. Physical access to the tape reservoir (4) is provided; when closed, it both displays the data and It acts as an upper body cover that protects the reservoir from external factors. The drive system is a motor-driven system that includes at least one electric motor, or the user's It is a manually operated system that works using physical force. 20 The energy storage unit consists of at least one rechargeable battery. The cutting / separation unit (6) drives the belt forwarded by the belt feeding mechanism (5). a guillotine that mechanically cuts to a predefined length or It is a blade mechanism. The printing element is applied to the front and rear surfaces of the device (10) in the preferred application of the invention. It is located. 8 In the preferred application of the invention, the device (10) and the mobile application in question (10) It includes at least one wireless communication module that enables data exchange between them. The subject matter could be wireless communication modules such as Bluetooth, Wi-Fi, RFID, etc. The device (10) prevents the patient from overdosing by adhering to the dose schedule received from the mobile application. It includes a time-based mechanical locking mechanism (3) to prevent it from locking. 5 The device (10) is digitally activated only when the correct dose time has arrived. Working Principle of the Invention The invention addresses technical problems arising from leaving dose control to the user's initiative. In order to solve this problem, a transdermal drug delivery method for the system described in the invention is as follows: It includes the following steps: 10 − The user places the medicine tape roll under the pop-up screen (1) of the device (10). Physical placement into the belt reservoir (4) − A dosage schedule via wireless communication through a mobile application creation and control unit of the device (10) from the said mobile application the incoming, pre-defined dose information, 15 - Outside of predefined dosage ranges or when appropriate conditions are not met at least one locking mechanism (3) is activated to prevent the device (10) from working stay; in this way the (10) belt advancement and application movements on the device the motor that performs the action of the belt feeding mechanism (5) The control unit in question must be 20 for at least one drive system operation that is manually operated. blocked by and the device (10) locked until the specified time interval eclipse, - When the appropriate time interval arrives according to the dosage plan received from the mobile application, the device (10) Automatic activation via the control unit, − The user activates the device (10) by pressing at least one of the multiple trigger systems (2) simultaneously. and the trigger signal generated by this pressing action is sent to the control unit. transmission, - The control unit evaluates the incoming signal and determines the appropriate time and dose. Verification and, if conditions are met, approval for activation of the drive system (motor). giving, 30 9 − The drive system, activated based on the control unit's approval, mechanically drives the medicine conveyor belt. advance it and when the determined length is reached, the belt cutting / separation unit (6) triggering the tape to be cut / separated, − The cut medication patch is applied to the skin surface with controlled pressure via a pressure element. The process involves applying and adhering the adhesive, ensuring contact with the skin, and all these steps take 5 minutes. throughout, the operating status and stages of the screen (1) located on the device (10) transmitting it to the user instantly, − After the application is successfully completed, the device's (10) control unit to be locked back in place and wait until the next dose time. It is the transition to mode 10. The device (10) mechanically extracts the medicine tapes, preferably stored in roll form, from the tape hopper (4). the skin is advanced, cut, and printed through a printing element applied from the front and back surfaces. It has a structure that allows for standard placement. Industrial Applicability of the Invention 15 This invention falls within the field of transdermal drug delivery; it involves controlled drug administration. These systems are evaluated within the scope of medical devices and digital health technologies. Especially for chronic diseases requiring regular doses, hormone therapies, pain management, and In addiction treatments, the safe, standardized, and traceable administration of medications is crucial. It can be used in home care, clinical and hospital settings to provide this service. 20 The invention is not limited to the above descriptions; a person skilled in the field can easily create the invention. It can present different applications. These are the claims of the invention and the protection sought. should be evaluated within this context. 30

Images